Pliant pauses enrollment for lung disease treatment trial

Pliant Therapeutics

07/02/2025 23:19

** Shares of drug developer Pliant Therapeutics  PLRX.O 
fall 65.5% to $2.72 in extended trading
    ** Company says a mid-stage trial testing experimental drug
bexotegrast in patients with idiopathic pulmonary fibrosis has
been paused 
    ** Says enrollment and dosing has been paused while a Data
Safety Monitoring Board (DSMB) reviews its trial data
    ** A DSMB refers to an independent group of experts that
reviews clinical trial data to ensure the safety of participants
and the validity of the trial
    ** Idiopathic pulmonary fibrosis is a chronic lung disease
that causes scarring and stiffening of the lung tissue
    ** Up to last close, stock down 40.9% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))